Search PubMedSearch

PubMed · 856365

Polymyositis.

Abstract

Polymyositis is a treatable and curable disease. Unfortunately, patients with polymyositis are still frequently diagnosed as having muscular dystrophy. It is important to have a high index of suspicion of polymyositis, and to recognize that the detailed symptoms and signs and the overall picture are different from the relatively clear-cut pattern of the muscular dystrophies. Treatment of polymyositis is rewarding, although it frequently requires considerable resilience from both patient and doctor to achieve the best results. A detailed search for an underlying aetiology should be made, and a carcinoma should be suspected in elderly patients and those with dermatomyositis. In patients in whom polymyositis is related to a carcinoma, the latter may be at a stage where total excision is possible.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W G Bradley. 1977. Polymyositis.. https://pubmed.ncbi.nlm.nih.gov/856365/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Neonatal cardiac transplantation. Intermediate-term results and incidence of rejection. Loma Linda University Pediatric Heart Transplant Group.

Early age at cardiac transplantation may favor successful engrafting with minimal chronic immunosuppression. Fifty-two newborns underwent orthotopic heart transplantation; 47 (90%) survived the operation, and 44 (85%) were late survivors. Actuarial survival was 92% at 1 month, 86% at 1 year, and 84% at 5 years. Forty-four infants who survived 12 weeks and the corresponding 100 rejection episodes were analyzed. Mean follow-up was 2.2 years. The mean number of rejections per year of follow-up was 1.2. No episodes of rejection were identified in six patients. Seven patients had a late rejection episode more than 1 year after transplantation, and only one had a late rejection episode after 2 years. Neonatal cardiac transplantation is effective and durable therapy for uncorrectable heart disease. Intermediate-term results are excellent. Severe rejection is uncommon, and few episodes occur after 1 year of follow-up.

Azathioprine